North America to Dominate the Multiplex Assays Market for Research & Development and Disease & Disorder Applications
The applications segment of the multiplex assays market is
categorized into research & development, diseases & disorders,
companion diagnostics, and other applications. The research &
development segment is expected to account for the largest share of the
multiplex assays market in 2016. Factors such as convenience in
performing the assays and faster results offered by multiplex assays are
driving the growth of this segment.
North America is expected to account for the largest share of the multiplex assays market in 2016. This region is estimated to account for 44.7% of the total market. Europe is the second-largest source, this regional market is driven by the availability of government funds.
Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=61593314
The adoption of companion diagnostics for increasing safety & efficacy of therapies, need for effective analytical platforms in research to reduce operational costs, advantages of multiplexing over traditional assays are the major drivers for the multiplex assays market. Increasing validation of biomarkers in molecular and protein diagnostics are expected to further drive the growth of the multiplex assays market.
Major players in the multiplex assays market include Luminex Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), and QIAGEN N.V. (Netherlands).
The end user segment of the multiplex assays market is segmented into academic and research institutes, hospitals, clinical laboratories, pharmaceutical and biotechnology companies, and other end users. The pharmaceutical and biotechnology companies segment is estimated to account for the largest share in 2016.
To Know More Download Sample Report Pages: http://www.marketsandmarkets.com/requestsample.asp?id=61593314
Article Credit: Healthcare DC(https://healthcaredc.wordpress.com)
North America is expected to account for the largest share of the multiplex assays market in 2016. This region is estimated to account for 44.7% of the total market. Europe is the second-largest source, this regional market is driven by the availability of government funds.
Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=61593314
The adoption of companion diagnostics for increasing safety & efficacy of therapies, need for effective analytical platforms in research to reduce operational costs, advantages of multiplexing over traditional assays are the major drivers for the multiplex assays market. Increasing validation of biomarkers in molecular and protein diagnostics are expected to further drive the growth of the multiplex assays market.
Major players in the multiplex assays market include Luminex Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), and QIAGEN N.V. (Netherlands).
The end user segment of the multiplex assays market is segmented into academic and research institutes, hospitals, clinical laboratories, pharmaceutical and biotechnology companies, and other end users. The pharmaceutical and biotechnology companies segment is estimated to account for the largest share in 2016.
To Know More Download Sample Report Pages: http://www.marketsandmarkets.com/requestsample.asp?id=61593314
Article Credit: Healthcare DC(https://healthcaredc.wordpress.com)
Comments
Post a Comment